The big pharmaceutical company provided a disappointing Q3 update.Shares of Eli Lilly (LLY -6.45%) were sinking 6.3% lower as of 11:11 a.m. ET on Wednesday. The sharp decline came after the big drugmaker announced its third-quarter results before the market opened. Lilly reported Q3 revenue of $11.4 billion, up 20% year over year. However, the consensus projection among analysts surveyed by LSEG was for revenue of $12.1 billion.The company posted net income of $970.3 million, or $1.07 per share, based on ge ...

Eli Lilly (LLY) reported $11.44 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 20.4%. EPS of $1.18 for the same period compares to $0.10 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $12.03 billion, representing a surprise of -4.92%. The company delivered an EPS surprise of -22.37%, with the consensus EPS estimate being $1.52.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

Topline Drug maker Eli Lilly's share price plunged Wednesday morning after the company reported worse third-quarter results than expected, especially in its weight-loss drug division, registering a rare misstep for the Wall Street darling. Eli Lilly stock is on pace for its worst loss since 2000. Getty Images Key Facts Shares of Eli Lilly dropped about 14% within 15 minutes of market open, tumbling toward the worst daily percentage decline for the stock since the 31% loss suffered Aug. 9, 2000 and the third ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and onl ...

Eli Lilly (LLY) came out with quarterly earnings of $1.18 per share, missing the Zacks Consensus Estimate of $1.52 per share. This compares to earnings of $0.10 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -22.37%. A quarter ago, it was expected that this drugmaker would post earnings of $2.64 per share when it actually produced earnings of $3.92, delivering a surprise of 48.48%. Over the last four quarters, the company has ...

Eli Lilly (LLY) shares tumbled 10% after its third-quarter results fell well short of analysts' estimates before the bell Wednesday. The pharmaceutical giant registered $11.44 billion in revenue—above last year's $9.50 billion but below the $12.18 billion consensus estimate of analysts polled by Visible Alpha—as weight-loss drugs Mounjaro and Zepbound continue to boost Eli Lilly's sales. Lilly swung to a profit of $970.3 million, or $1.07 per share, but still well below the $1.69 billion and $1.87 per shar ...

Oct. 30, 2024 For release: Immediately Refer to: Jordan Bishop; jordan.bishop@lilly.com; (317) 374-1878 (Media) Joe Fletcher; jfletcher@lilly.com; (317) 296-2884 (Investors) Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products • Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue fro ...

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024.Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter and slashed its full-year adjusted profit guidance, sending its stock tumbling roughly 10%.The drugmaker now expects full-year adjusted earnings of between $13.02 to $13.52 per share, down from previous guidance of $16.10 to $16.60 per share. Eli Lilly also lowered the high-end of its revenue outlook ...

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue from the olanzapine portfolio, total revenue increased 42%, and non-incretin revenue increased 17%. Q3 2024 EPS increased to $1.07 on a reported basis and $1.18 on a non-GAAP basis, both inclusive of $3.08 of acquired IPR&D charges. 2024 revenue guidance range updated to $45.4 to $46.0 b ...

Eli Lilly has a number of lucrative opportunities that should serve as tailwinds for sustained growth. For the past couple of years, two of the biggest themes fueling the stock market to new highs are breakthroughs in the weight loss market and euphoria around artificial intelligence (AI). What if I told you that there's a company that operates across both of these opportunities, and that despite a 61% gain in its share price during the past year, the stock is still a compelling buy? Let's explore what's fu ...